一项在转移性去势抵抗性前列腺癌患者中开展[177Lu]Lu-HTK03170联合个体化剂量学的I/II期研究:临床试验方案
这是一项首次在人体中开展、开放标签、单中心的I/II期试验,评估新型PSMA靶向放射性药物[177Lu]Lu-HTK03170在PSMA阳性转移性去势抵抗性前列腺癌(mCRPC)患者中的安全性、剂量学与疗效。I期采用传统3+3剂量递增设计确定最大耐受注射活度并联合个体化剂量学,II期采用Simon两阶段设计评估客观缓解率,每例最多接受7个周期、每8周给药一次。
要点
- I期采用3+3剂量递增设计,确定[177Lu]Lu-HTK03170首次注射的最大耐受注射活度,后续注射按个体化剂量学计算活度
- 每例参与者最多接受7个治疗周期,每8周给药一次
- II期主要终点为按RECIST 1.1定义的客观缓解率,采用Simon两阶段设计
核心结论
- 这项正在进行的首次人体试验旨在确定[177Lu]Lu-HTK03170在PSMA阳性mCRPC患者中的安全性、剂量学和初步疗效,其结果将为该药的临床开发提供依据。
研究设计与样本
- 首次人体、开放标签、单中心I/II期试验,评估[177Lu]Lu-HTK03170的安全性与疗效。
- I期采用传统3+3剂量递增设计,确定首次注射的最大耐受注射活度,随后按个体化剂量学计算每次后续注射的活度,预计入组最多18例患者。
- II期采用Simon两阶段设计评估疗效,预计入组约32例患者。
- 纳入PSMA阳性mCRPC且经雄激素受体通路抑制剂治疗后进展(联合或不联合紫杉烷类化疗)的患者。
- 每例参与者最多接受7个治疗周期,每8周给药一次。
主要发现
- I期主要终点为确定最大耐受注射活度和安全性特征,通过剂量限制性毒性发生情况和正常器官吸收剂量测量进行评估。
- II期主要终点为按RECIST 1.1定义的客观缓解率。
- 次要终点包括前列腺特异性抗原缓解率、无进展生存期、总生存期、至症状性骨骼事件时间和生活质量。
- 探索性终点包括评估循环肿瘤DNA/RNA作为治疗反应潜在生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals, such as the novel [177Lu]Lu-HTK03170, present a promising therapeutic option for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-HTK03170, being used in humans for the first time in this trial, was specifically designed to improve tumor specificity and minimize off-target toxicity, addressing the limitations of existing PSMA radiopharmaceutical therapies. This phase I/II clinical trial aims to evaluate the safety, dosimetry, and efficacy of [177Lu]Lu-HTK03170 in patients with PSMA-positive mCRPC who have progressed on androgen receptor pathway inhibitors with or without taxane chemotherapy. Methods: This first-in-human, open-label, single-center phase I/II trial is designed to assess the safety and efficacy of [177Lu]Lu-HTK03170. Phase I follows a traditional 3 + 3 dose-escalation design to determine the maximum tolerated injected activity of the first injection of [177Lu]Lu-HTK03170, followed by personalized dosimetry to calculate the activity of each subsequent injection. Dose-limiting toxicities will be used to guide dose adjustments, with personalized dosimetry used to monitor absorbed doses to critical organs. Up to 18 patients are expected to be enrolled in phase I. Phase II, using a Simon 2-stage design, will evaluate the treatment's efficacy, with approximately 32 patients expected to enroll. Each participant will receive up to 7 treatment cycles administered every 8 wk. In phase I, the primary endpoints include determining the maximum tolerated injected activity and safety profile, which will be assessed by the occurrence of dose-limiting toxicities and the measurement of absorbed doses to normal organs. In phase II, the primary endpoint is the objective response rate as defined by RECIST 1.1. Secondary endpoints include prostate-specific antigen response rate, progression-free survival, overall survival, time to symptomatic skeletal events, and quality of life. Exploratory endpoints include evaluating circulating tumor DNA/RNA as potential biomarkers for treatment response. Conclusion: This ongoing first-in-human trial aims to establish the safety, dosimetry, and preliminary efficacy of [177Lu]Lu-HTK03170 in patients with PSMA-positive mCRPC. The results of this study will inform the clinical development of [177Lu]Lu-HTK03170 as a potential treatment option for mCRPC.
引用
- Harsini S, Soleimani M, Wilson D, et al. A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol. J Nucl Med. 2025. PMID: 40306965. doi:10.2967/jnumed.124.269064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。